Nanoviricides (NNVC) Non Operating Income (2010 - 2026)
Nanoviricides (NNVC) posted Non Operating Income of $40885.0 for Q1 2026, up 228.26% sequentially from $12455.0 in Q4 2025, and up 26.29% YoY from $32373.0 in Q1 2025.
Nanoviricides (NNVC) Non Operating Income (2010 - 2026) Analysis & Trends
Nanoviricides has reported Non Operating Income for 17 years, with the latest figure at $40885.0 in Q1 2026.
- Quarterly Non Operating Income rose 26.29% year-over-year to $40885.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $84689.0 (down 39.65% YoY) and the FY2025 annual result came in at $124679.0, down 43.83% from the prior year.
- Non Operating Income climbed to $40885.0 in Q1 2026 per NNVC's latest filing, from $12455.0 in the prior quarter.
- Over five years, Non Operating Income peaked at $107937.0 in Q1 2023 and troughed at -$4789.0 in Q1 2022.
- A 5-year average of $45558.9 and a median of $40885.0 in 2026 frame the typical range for Non Operating Income.
- The widest YoY moves for Non Operating Income: up 16024.73% in 2022, down 867.47% in 2022.
- Over 5 years, Non Operating Income stood at $88860.0 in 2022, then declined by 21.43% to $69819.0 in 2023, then slumped by 54.8% to $31560.0 in 2024, then plunged by 60.54% to $12455.0 in 2025, then surged by 228.26% to $40885.0 in 2026.
- According to Business Quant data, Non Operating Income over the past three periods registered $40885.0, $12455.0, and $11627.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Op. Inc. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 234.30 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | - |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | -53.64 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | -51.63 Mn |
| 10 | Nanoviricides | 28.74 Mn | 25.53 Mn | - | 40,885.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 40,885.00 |
| Dec 31, 2025 | 12,455.00 |
| Sep 30, 2025 | 11,627.00 |
| Jun 30, 2025 | 19,722.00 |
| Mar 31, 2025 | 32,373.00 |
| Dec 31, 2024 | 31,560.00 |
| Sep 30, 2024 | 41,023.00 |
| Jun 30, 2024 | 35,374.00 |
| Mar 31, 2024 | 53,927.00 |
| Dec 31, 2023 | 69,819.00 |
| Sep 30, 2023 | 62,845.00 |
| Jun 30, 2023 | 106,380.00 |
| Mar 31, 2023 | 107,937.00 |
| Dec 31, 2022 | 88,860.00 |
| Sep 30, 2022 | 51,718.00 |
| Jun 30, 2022 | 12,786.00 |
| Mar 31, 2022 | -4,789.00 |
| Dec 31, 2021 | -558.00 |
| Sep 30, 2021 | -703.00 |
| Jun 30, 2021 | 1,394.00 |